GSK has pulled off a major coup, replacing outgoing chief science officer Patrick Vallance with Calico and former Roche/Genentech whizz, Dr Hal Barron with a bumper pay package that could b
AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL).
